PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

TOS statement on oral GLP-1s

2025-04-22
(Press-News.org) ROCKVILLE, MD-Advances in evidence-based obesity medications and treatment options are critical for the millions of individuals living with the chronic disease. The Obesity Society is encouraged by the development of new options that are effective, safe, and convenient for consumers. 

Last week, results released for the ACHIEVE-1 Phase 3 clinical trial suggest that a new medication, Orforglipron, an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken once daily led to an average weight loss of 7.9% in individuals with diabetes and impaired glycemic control.  Researchers noted that participant weight loss had not yet plateaued hinting that additional weight reduction from the drug could be realized. 

“What is exciting about the study and results for Orforglipron is that the safety and tolerability of an oral GLP-1 medication was consistent with injectable therapies.  Individuals with diabetes improved their hemoglobin A1C by an average of 1.3% to 1.6%, with more than 65% achieving a level equal or below 6.5% from a baseline of 8%,” stated Marc-Andre Cornier, MD FTOS, president of The Obesity Society (TOS). “This oral medication may be easy for individuals to take consistently and could prove to be more accessible than weekly injections.” 

The positive news about the results of Orforglipron came on the tail of the announcement that a different Phase 3 clinical trial for another oral daily drug, danuglipron, was being halted. An asymptomatic participant in one of the dose-optimization studies experienced a potential drug-induced liver injury that resolved with cessation of the medication. After careful review of the case and other data, the company made the decision to stop the development of the drug. 

“Clinical trials allow researchers to measure the safety and health outcomes associated with obesity medications. In this case, the study brought to light safety concerns and the trial was halted,” noted Cornier. “Obesity research is an important factor in determining best approaches to care and treatment, we need to ensure that as a nation we invest in and support studies that advance medicine.”

###  

The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects. Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity. For more information, visit www.obesity.org. 

END



ELSE PRESS RELEASES FROM THIS DATE:

Pulmonary fibrosis has no cure. Could a cancer drug hold the answer?

2025-04-22
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide. IPF is rapidly progressive and causes scarring in the lungs, making it difficult to breathe. Approximately 50% of patients die within three years of diagnosis, and current treatments can only slow the disease — not stop or reverse it.  In a study published in the Journal ...

Trial explores drug-free approach to treat ADHD symptoms in children exposed to alcohol before birth

2025-04-22
Researchers at UCLA Health are launching the first clinical trial to test whether a wearable device that delivers gentle nerve stimulation during sleep could ease ADHD symptoms in children with prenatal alcohol exposure. Children exposed to alcohol in the womb have a heightened risk of developing ADHD-like symptoms including hyperactivity, impulsivity and executive function deficits such as difficulty paying attention, remembering, and organizing their behavior. Prenatal alcohol exposure affects about 5% of children in the U.S. with the majority developing these symptoms. ...

New research points out a promising strategy for treating metastatic medulloblastoma

2025-04-22
Researchers at Baylor College of Medicine, Texas Children’s Hospital, the Hospital for Sick Children in Toronto and collaborating institutions reveal in Nature Cell Biology a strategy that helps medulloblastoma, the most prevalent malignant brain tumor in children, spread and grow on the leptomeninges, the membranes surrounding the brain and spinal cord. They discovered a novel line of communication between metastatic medulloblastoma and leptomeningeal fibroblasts that mediates recruitment and reprogramming of the latter to support tumor growth. The findings suggest that disrupting this communication offers a potential opportunity to treat this devastating ...

Light fields with extraordinary structure: plasmonic skyrmion bags

2025-04-22
“Our results add another chapter to the emerging field of skyrmion research,” proclaims Prof. Harald Giessen, head of the Fourth Physics Institute at the University of Stuttgart, whose group achieved this breakthrough. The team demonstrated the existence of “skyrmion bags” of light on the surface of a metal layer. A better understanding of physical phenomena Skyrmions are a mathematical description of vortex-like structures that help researchers better understand fundamental physical relationships. In recent years, this theoretical ...

DNA origami guides new possibilities in the fight against pancreatic cancer

2025-04-22
CHAMPAIGN, Ill. — One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. A new study uses DNA origami structures to selectively deliver fluorescent imaging agents to pancreatic cancer cells without affecting normal cells. The study, led by University of Illinois Urbana-Champaign mechanical science and engineering professor Bumsoo Han and professor Jong Hyun Choi at Purdue University, found that specially engineered DNA origami structures carrying imaging dye packets can specifically target human KRAS mutant ...

PREPSOIL launches assessment tool for soil living lab and lighthouse initiatives

2025-04-22
This tool is specifically designed to assess how well your initiative aligns with the EU Mission: A Soil Deal for Europe (Mission Soil) criteria for Soil Living Labs and Lighthouses, as further defined by the PREPSOIL taxonomy.  Should your initiative meet the necessary criteria, you will be invited to participate in a more detailed assessment developed by the SOILL-Startup project. This next phase will provide an opportunity to join a network of 100 Soil Living Labs and ...

Lebanon crisis driving parents to seek unregulated “shadow” education, study shows

2025-04-22
Political and social crisis in Lebanon has forced parents to seek unregulated “shadow” education for their children, a new study shows. The government’s ongoing neglect of public education is intensifying social inequality, experts have warned. The current sectarian power-sharing arrangement has led to a diminished focus on schools, fostering privatization. The study shows how upheavals in Lebanon have exacerbated educational challenges for families across all socioeconomic groups, leading to an increasing reliance on the unregulated shadow education sector, particularly private ...

The AGA Research Foundation awards $2.4 million in digestive health research funding

2025-04-22
Bethesda, MD (April 22, 2025) — The American Gastroenterological Association (AGA) is proud to announce the selection of 74 recipients to receive $2.4 million in research funding through the annual AGA Research Foundation Awards Program. AGA also announces today the addition of 10 pilot grants, totaling $400,000 in funding, to the 2026 awards portfolio to ensure that scientific discovery continues despite federal funding cuts. “Since we established the AGA Research Foundation in 1984, AGA has been unwavering in the commitment to supporting ...

A repurposed anti-inflammatory drug may help treat alcohol use disorder and related pain

2025-04-22
LA JOLLA, CA—A preclinical study from scientists at Scripps Research finds that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity—two issues that commonly co-occur with alcohol use disorder (AUD). The results, published in JCI Insight on April 22, 2025, suggest that the drug apremilast—a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation—could be repurposed as a dual-acting therapy for AUD, particularly in individuals who have pain during and after alcohol use. AUD ...

Obesity disrupts “reaction time” to starvation in mice

2025-04-22
Researchers led by Keigo Morita and Shinya Kuroda of the University of Tokyo have revealed a temporal disruption in the metabolism of obese mice when adapting to starvation despite no significant structural disruptions in the molecular network. This is a breakthrough discovery as research including the temporal dimension in biology has been notoriously laborious and extracting systematic insight from big data has been difficult. Thus, this study paves the way for further research into more general metabolic processes, such as food intake and disease progression. The findings were published in the journal Science Signaling. Living beings need to continuously extract energy from “food” ...

LAST 30 PRESS RELEASES:

Breathable yet protective: Next-gen medical textiles with micro/nano networks

Frequency-engineered MXene supercapacitors enable efficient pulse charging in TENG–SC hybrid systems

Developed an AI-based classification system for facial pigmented lesions

Achieving 20% efficiency in halogen-free organic solar cells via isomeric additive-mediated sequential processing

New book Terraglossia reclaims language, Country and culture

The most effective diabetes drugs don't reach enough patients yet

Breast cancer risk in younger women may be influenced by hormone therapy

Strategies for staying smoke-free after rehab

Commentary questions the potential benefit of levothyroxine treatment of mild hypothyroidism during pregnancy

Study projects over 14 million preventable deaths by 2030 if USAID defunding continues

New study reveals 33% gap in transplant access for UK’s poorest children

Dysregulated epigenetic memory in early embryos offers new clues to the inheritance of polycystic ovary syndrome (PCOS)

IVF and IUI pregnancy rates remain stable across Europe, despite an increasing uptake of single embryo transfer

It takes a village: Chimpanzee babies do better when their moms have social connections

From lab to market: how renewable polymers could transform medicine

Striking increase in obesity observed among youth between 2011 and 2023

No evidence that medications trigger microscopic colitis in older adults

NYUAD researchers find link between brain growth and mental health disorders

Aging-related inflammation is not universal across human populations, new study finds

University of Oregon to create national children’s mental health center with $11 million federal grant

Rare achievement: UTA undergrad publishes research

Fact or fiction? The ADHD info dilemma

Genetic ancestry linked to risk of severe dengue

Genomes reveal the Norwegian lemming as one of the youngest mammal species

Early birds get the burn: Monash study finds early bedtimes associated with more physical activity

Groundbreaking analysis provides day-by-day insight into prehistoric plankton’s capacity for change

Southern Ocean saltier, hotter and losing ice fast as decades-long trend unexpectedly reverses

Human fishing reshaped Caribbean reef food webs, 7000-year old exposed fossilized reefs reveal

Killer whales, kind gestures: Orcas offer food to humans in the wild

Hurricane ecology research reveals critical vulnerabilities of coastal ecosystems

[Press-News.org] TOS statement on oral GLP-1s